Table 3.
PJP patients (n = 40) | non-PJP patients (n = 40) | *P-Value | |
---|---|---|---|
Age (years) | 52 (23-73) | 49 (39-60) | 0.383 |
Males, n% | 26 (65) | 26 (65) | 0.258 |
Lymphocyte subsets | |||
CD28+ CD4+ T cells (%) | 83.74 (32.91-99.50) | 90.18 (83.27-97.08) | 0.243 |
CD28+CD8+ T cells (%) | 40.42 (23.6157.22) | 57.99 (37.74-78.24) | 0.079 |
HLA-DR+CD3+ T cells (%) | 32.14 (16.46-71.84) | 24.64 (11.69-27.79) | 0.400 |
HLA-DR+CD8+ T cells (%) | 65.02 (41.85-88.19) | 46.22 (27.79-64.65) | 0.079 |
CD45RA+CD4+ T cells (%) | 25.86 (9.22-42.50) | 30.80 (8.44-53.17) | 0.841 |
CD45RO+CD4+ T cells (%) | 74.14 (57.50-90.78) | 69.20 (46.86-91.55) | 0.842 |
CD4+CD25+CD127- cells (%) | 2.58 (1.06-4.09) | 2.75 (1.11-4.40) | 0.905 |
CD45RA+ Treg cells (%) | 0.37 (0.10-0.63) | 0.33 (0.11-1.93) | 0.497 |
CD45RO+ Treg cells (%) | 2.21 (0.87-3.55) | 2.02 (0.84-3.21) | 0.661 |
PJP, Pneumocystis jiroveci pneumonia; *Comparisons were performed between PJP group and non-PJP group using Mann-Whitney U test chi-square test. Data are presented as number (percentage), means ± SD, or medians (2.5th - 97.5th centiles).